Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Van Lint

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Cancer Immunology, Immunotherapy : CII|June 1, 2014
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formulaSandra Van Lint, Sofie Wilgenhof, Carlo Heirman, et al.
Molecular Therapy. Nucleic Acids|November 24, 2020
The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of AdministrationLien Van Hoecke, Kenny Roose, Marlies Ballegeer, et al.
Cellular and Molecular Life Sciences : CMLS|January 20, 2019
A novel leptin receptor antagonist uncouples leptin's metabolic and immune functionsLennart Zabeau, Joris Wauman, Julie Dam, et al.
Nature Communications|August 26, 2018
Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopesLien Van Hoecke, Sandra Van Lint, Kenny Roose, et al.
Oncotarget|February 16, 2015
Targeting the tumor microenvironment to enhance antitumor immune responsesKevin Van der Jeught, Lukasz Bialkowski, Lidia Daszkiewicz, et al.
Journal of Autoimmunity|November 24, 2018
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in miceAnje Cauwels, Sandra Van Lint, Dominiek Catteeuw, et al.
Scientific Reports|November 4, 2021
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAEAnje Cauwels, Sandra Van Lint, Elke Rogge, et al.
Oncotarget|February 13, 2014
Immunogenicity of targeted lentivectorsCleo Goyvaerts, De Groeve Kurt, Sandra Van Lint, et al.
Cancer Research|February 17, 2012
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapySandra Van Lint, Cleo Goyvaerts, Sarah Maenhout, et al.
NPJ Vaccines|July 28, 2020
Specific targeting of IL-1β activity to CD8<sup>+</sup> T cells allows for safe use as a vaccine adjuvantBram Van Den Eeckhout, Lien Van Hoecke, Elianne Burg, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Cancer Immunology, Immunotherapy : CII|June 1, 2014
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formulaSandra Van Lint, Sofie Wilgenhof, Carlo Heirman, et al.
Molecular Therapy. Nucleic Acids|November 24, 2020
The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of AdministrationLien Van Hoecke, Kenny Roose, Marlies Ballegeer, et al.
Cellular and Molecular Life Sciences : CMLS|January 20, 2019
A novel leptin receptor antagonist uncouples leptin's metabolic and immune functionsLennart Zabeau, Joris Wauman, Julie Dam, et al.
Nature Communications|August 26, 2018
Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopesLien Van Hoecke, Sandra Van Lint, Kenny Roose, et al.
Oncotarget|February 16, 2015
Targeting the tumor microenvironment to enhance antitumor immune responsesKevin Van der Jeught, Lukasz Bialkowski, Lidia Daszkiewicz, et al.
Journal of Autoimmunity|November 24, 2018
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in miceAnje Cauwels, Sandra Van Lint, Dominiek Catteeuw, et al.
Scientific Reports|November 4, 2021
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAEAnje Cauwels, Sandra Van Lint, Elke Rogge, et al.
Oncotarget|February 13, 2014
Immunogenicity of targeted lentivectorsCleo Goyvaerts, De Groeve Kurt, Sandra Van Lint, et al.
Cancer Research|February 17, 2012
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapySandra Van Lint, Cleo Goyvaerts, Sarah Maenhout, et al.
NPJ Vaccines|July 28, 2020
Specific targeting of IL-1β activity to CD8<sup>+</sup> T cells allows for safe use as a vaccine adjuvantBram Van Den Eeckhout, Lien Van Hoecke, Elianne Burg, et al.
Pageof 4